Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register
Authors:
- Elsa Vieira-SousaEVElsa Vieira-Sousa
- Mónica EusébioMEMónica Eusébio
- Pedro Ávila-RibeiroPÁPedro Ávila-Ribeiro
- Nikita KhmelinskiiNKNikita Khmelinskii
- Rita Cruz-MachadoRCRita Cruz-Machado
- Teresa Martins RochaTRTeresa Martins Rocha
- Miguel BernardesMBMiguel Bernardes
- Daniela Santos-FariaDSDaniela Santos-Faria
- Joana Leite SilvaJSJoana Leite Silva
- Helena SantosHSHelena Santos
- Cláudia MiguelCMCláudia Miguel
- Pedro CarvalhoPCPedro Carvalho
- 1 August 2019
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 47 (5) , 690-700
Abstract
Objective.: To assess longterm effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with psoriatic arthritis (PsA) registered in the Rheumatic Diseases Portuguese Register, exposed to at least 1 TNFi, prospectively followed between 2001 and 2017.Methods.: Kaplan-Meier analysis was performed for first-, second-, and third-line TNFi. Responses included European League Against Rheumatism (EULAR) criteria, Disease Activity Index for Psoriatic Arthritis (DAPSA), minimal disease activity (MDA), and Ankylosing Spondylitis Disease Activity Score (ASDAS) at 3 and 6 months. Baseline predictors of discontinuation and response were studied using Cox and multivariable multinomial/logistic regression models.Results.: The 750 patients with PsA showed drug retention of 4.1 ± 3.4 years (followup 5.8 ± 3.8 yrs) for first TNFi. Switching to a second (189 patients) or third (50 patients) TNFi further decreased survival by 1.1 years. Female sex, higher baseline 28-joint count Disease Activity Score, and infliximab were predictors of first TNFi discontinuation. After 6 months of the first TNFi, 48.7% of patients achieved a good EULAR criteria response and 20.9% were in DAPSA remission. There were 11.4% in MDA, and 56.4% had a good ASDAS. Responses to the second TNFi were significantly inferior compared to responses to the first TNFi. Female sex and higher baseline Health Assessment Questionnaire–Disability Index were negatively associated with good EULAR response at 3 months, and obesity decreased the chance of response at 6 months.Conclusion.: In this study, switching to a second or third TNFi was associated with significantly lower drug survival and response rates for patients with axial and peripheral PsA subtypes. More successful therapeutic approaches will require considering the effect of sex and obesity on TNFi effectiveness.Keywords
This publication has 23 references indexed in Scilit:
- Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritisRheumatology, 2017
- Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registryClinical Rheumatology, 2017
- Reuma.pt – a case studyActa Medica Portuguesa, 2016
- Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicityExpert Opinion on Biological Therapy, 2014
- Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD studyAnnals of the Rheumatic Diseases, 2013
- Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registryArthritis & Rheumatism, 2010
- Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics RegisterArthritis Research & Therapy, 2009
- The LUNDEX, a new index of drug efficacy in clinical practice: Results of a five‐year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern SwedenArthritis & Rheumatism, 2006
- Adjusting Survival Curves for Confounders: A Review and a New MethodAmerican Journal of Epidemiology, 1996
- Psoriatic arthritisSeminars in Arthritis and Rheumatism, 1973